Your session is about to expire
← Back to Search
Gene Therapy for Duchenne Muscular Dystrophy
Study Summary
This trial will assess the safety and effectiveness of SGT-003, an IV infusion, in treating Duchenne muscular dystrophy in children ages 4-8. All participants will be monitored for 5 years.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is recruitment for this experiment still in progress?
"The information hosted on clinicaltrials.gov states that no participants are necessary for this particular medical trial at the moment, despite it being first posted on January 15th 2024 and last edited November 14th 2023. However, there are 91 other studies actively recruiting right now."
Are octogenarians eligible to participate in this trial?
"To be eligible for this particular trial, applicants must fall between the ages of 4 and 7. Simultaneously, there are 61 studies aimed at children under 18 years old as well as 54 other trials targeting elderly people over 65."
Is it possible for me to participate in this clinical investigation?
"To fulfill the eligibility criteria of this research, participants need to be diagnosed with duchenne muscular dystrophy and between 4-7 years old. Approximately 6 individuals must take part in the trial for it to proceed."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger